about
Mucus penetrating nanoparticles: biophysical tool and method of drug and gene deliveryEffects of hormonal contraception on antiretroviral drug metabolism, pharmacokinetics and pharmacodynamicsVaginal drug distribution modelingThe importance of the vaginal delivery route for antiretrovirals in HIV prevention.Intravaginal rings as delivery systems for microbicides and multipurpose prevention technologies.Patient acceptability and satisfaction with a low-dose solubilized vaginal estradiol softgel capsule, TX-004HR.Nanoparticle-based drug delivery to the vagina: a review.Examining the efficacy, safety, and patient acceptability of the combined contraceptive vaginal ring (NuvaRing).What do portuguese women prefer regarding vaginal products? Results from a cross-sectional web-based surveyFormulation, In Vitro and In Vivo Pharmacokinetics of Anti-HIV Vaginal Bioadhesive GelProgesterone vaginal ring for luteal support.Maternal hormonal contraceptive use and offspring overweight or obesityLocal Effects of Vaginally Administered Estrogen Therapy: A Review.Pharmacokinetic study to compare the absorption and tolerability of two doses of levonorgestrel following single vaginal administration of levonorgestrel in Carraguard gel: a new formulation for "dual protection" contraceptionEffect of a single vaginal administration of levonorgestrel in Carraguard gel on the ovulatory process: a potential candidate for "dual protection" emergency contraception.Vaginal delivery of contraceptives.Development and evaluation of an in vitro vaginal model for assessment of drug's biopharmaceutical properties: curcumin.The paradoxical effects of using antiretroviral-based microbicides to control HIV epidemicsCharacteristics of women screened for a contraceptive intravaginal ring study in Kisumu, Kenya, 2014Vaginal drug delivery systems for HIV prevention.Enhanced vaginal drug delivery through the use of hypotonic formulations that induce fluid uptake.Mucus-penetrating nanoparticles for vaginal drug delivery protect against herpes simplex virus.Comparing the effects of low-dose contraceptive pills to control dysfunctional uterine bleeding by oral and vaginal methods.Preparation and characterisation of fluconazole vaginal films for the treatment of vaginal candidiasis.Vaginal gel drug delivery systems: understanding rheological characteristics and performance.Medical treatment of idiopathic heavy menstrual bleeding. What is new? An evidence based approach.Counseling on vaginal delivery of contraceptive hormones: implications for women's body knowledge and sexual health.Advanced topical drug delivery system for the management of vaginal candidiasis."Per vaginam" topical use of hormonal drugs in women with symptomatic deep endometriosis: a narrative literature review.Degradable bioadhesive nanoparticles for prolonged intravaginal delivery and retention of elvitegravir.Women's experiences, preferences and perceptions regarding vaginal products: Results from a cross-sectional web-based survey in Portugal.Effect of mifepristone on endometrial matrix metalloproteinase expression and leukocyte abundance in new medroxyprogesterone acetate users.Pharmacokinetic profiles of controlled-release hydrogel polymer vaginal inserts containing misoprostol.A questionnaire-based audit to assess overall experience and convenience among patients using vaginal progesterone tablets (Lutigest®) for luteal phase support during IVF treatment.Thermosensitive hydrogels a versatile concept adapted to vaginal drug delivery.Oral and depot progestin therapy for endometriosis: towards a personalized medicine.Development of cyclodextrin hydrogels for vaginal delivery of dehydroepiandrosterone.Characterization of anastrozole effects, delivered by an intravaginal ring in cynomolgus monkeys.Sildenafil vaginal suppositories: preparation, characterization, in vitro and in vivo evaluation.Long-term vaginal administration ofLactobacillus rhamnosusas a complementary approach to management of bacterial vaginosis
P2860
Q26823541-05099B07-31F7-4A89-AE4F-8B235093C0DAQ26998835-D00A55DC-1822-40E4-86B0-8A62C0C44A66Q28088306-A97B95D6-683F-4381-A99D-634D20D0B7E9Q30414890-A260E060-6B52-465A-AC9A-92F5F2DA794CQ30447923-C0357D08-EC06-44A3-BDC9-E062333E0F43Q30490900-44C3BF18-C8D9-4B12-BFBB-71EB8FE1FF35Q34079533-88F3C428-9090-496E-BF9C-BC0FEB8ECEC2Q34345741-25D04B10-71C3-4C8B-B9CD-4467FA752BE0Q34785676-565230AE-1198-413E-9DC8-45C87848EB18Q35064834-00F6B330-49CA-4753-B8AD-3ABF3E80D61FQ35126328-120B1977-3D63-4830-9FEE-D61CEBC32445Q35195351-EEA3555A-5BC8-4330-8FA2-CE5048B5AD16Q35654573-80DD401B-EC5E-4604-BABB-112ADF89FB59Q36016276-9B8978CA-AE2F-4AE9-B710-AC96BCF38AE6Q36143474-72342E0A-7828-41CE-8E50-5486398DBD65Q36316884-61A4C68D-E894-4E2A-B2C5-BD73CE96921DQ36442149-C9FEB140-175F-4CC8-921F-FE7BC70306D7Q36749580-BF5794FD-3B12-45EB-A087-6EB6FC7E944FQ37098147-2747438B-E781-43E9-96B4-690AC81ECFD5Q37149107-9D453653-B997-4988-ABB5-B0AA16A208A3Q37158237-254A830B-096E-4DBD-9368-C48AFE751CB8Q37280337-D5A82798-4510-4612-B368-8963B092E8E3Q37382701-94EF5F2E-E7AF-42B3-B49C-5CE80B56A631Q37423998-266F7F4E-EA89-415A-8AAF-7ADF5500A466Q37897568-767CCEFD-3FC4-4193-99B9-551472A29166Q38057112-01BB7C0E-1E97-44A4-B70B-0E3CFDBD2C35Q38132846-BB3D0A77-C5D3-4CAB-872B-3494E259A71CQ38222794-BEDC064C-4889-4DA0-A8E0-F251D6C3A45CQ38664714-59A2F757-3638-4AEC-A293-3E83FE24A3E5Q40075268-A4DC1761-C575-4281-89A4-7175CF75BF3EQ41588595-AEC1FD3B-2288-4524-82CD-26492281F00CQ46251881-57BA2B3E-E6A8-4FAE-82DF-2FB832AFE70DQ46856805-F719AD04-7091-4EEE-B5A8-318FAC8D7F36Q47134609-CCC9E235-5D11-4F44-BD30-264D7EA61238Q47591959-7C565162-54F1-43FF-92D1-F877C2506424Q47671265-06F66A38-E70D-456C-8E2F-8952CAF9E4CDQ50866349-97839B53-6D49-4449-8DC2-B430F42FEB4DQ51074581-47515141-95D3-4F38-A856-9E4DBD4E8A36Q51232624-412E73F7-F099-42E2-BEAF-BF2CCB554758Q56767192-0B262C47-6F55-4602-9973-A570850E3456
P2860
description
2004 nî lūn-bûn
@nan
2004 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Why consider vaginal drug administration?
@ast
Why consider vaginal drug administration?
@en
Why consider vaginal drug administration?
@nl
type
label
Why consider vaginal drug administration?
@ast
Why consider vaginal drug administration?
@en
Why consider vaginal drug administration?
@nl
prefLabel
Why consider vaginal drug administration?
@ast
Why consider vaginal drug administration?
@en
Why consider vaginal drug administration?
@nl
P2093
P1476
Why consider vaginal drug administration?
@en
P2093
Edio Zampaglione
Edward Baker
Leslie Miller
Marc Kaptein
Nancy J Alexander
Ulrich Karck
P356
10.1016/J.FERTNSTERT.2004.01.025
P407
P577
2004-07-01T00:00:00Z